Table 1.

Correlation Between FOXP3 Expression and the Clinicopathological Features of the BRCA Cases

Characteristic	Low Expression of FOXP3	High Expression of FOXP3	p	Statistic	Method
n	532	533
T stage, n (%)			0.007	12.12	Chisq. test
T1	138 (13%)	137 (12.9%)
T2	288 (27.1%)	327 (30.8%)
T3	79 (7.4%)	58 (5.5%)
T4	25 (2.4%)	10 (0.9%)
N stage, n (%)			0.910	0.54	Chisq. test
N0	255 (24.4%)	252 (24.1%)
N1	174 (16.6%)	175 (16.7%)
N2	54 (5.2%)	62 (5.9%)
N3	37 (3.5%)	37 (3.5%)
M stage, n (%)			0.434	0.61	Chisq. test
M0	432 (47.5%)	457 (50.3%)
M1	12 (1.3%)	8 (0.9%)
Pathologic stage, n (%)			0.377	3.1	Chisq. test
Stage I	96 (9.2%)	84 (8.1%)
Stage II	289 (27.7%)	317 (30.4%)
Stage III	122 (11.7%)	116 (11.1%)
Stage IV	11 (1.1%)	7 (0.7%)
Race, n (%)			0.022	7.6	Chisq. test
Asian	24 (2.5%)	36 (3.7%)
Black or African American	78 (8%)	101 (10.3%)
White	389 (39.9%)	348 (35.7%)
Age, n (%)			0.025	5.04	Chisq. test
<=60	275 (25.8%)	313 (29.4%)
>60	257 (24.1%)	220 (20.7%)
Histological type, n (%)			0.162	1.95	Chisq. test
Infiltrating Ductal Carcinoma	353 (36.8%)	404 (42.1%)
Infiltrating Lobular Carcinoma	106 (11.1%)	96 (10%)
PR status, n (%)			< 0.001		Fisher. test
Negative	131 (12.9%)	207 (20.4%)
Indeterminate	3 (0.3%)	1 (0.1%)
Positive	372 (36.6%)	302 (29.7%)
ER status, n (%)			< 0.001		Fisher. test
Negative	76 (7.5%)	161 (15.8%)
Indeterminate	1 (0.1%)	1 (0.1%)
Positive	430 (42.3%)	348 (34.2%)
HER2 status, n (%)			0.072	5.26	Chisq. test
Negative	269 (37.5%)	279 (38.9%)
Indeterminate	5 (0.7%)	7 (1%)
Positive	61 (8.5%)	96 (13.4%)
Age, median (IQR)	60 (50, 69)	57 (48, 66)	0.017	153,707.5	Wilcoxon